Abstracts tagged "prognostic factors"

Abstract Number: 2008 • ACR Convergence 2020
Should We Use Glucocorticoid in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
Emilie Sapart¹, Tatiana Sokolova¹, Stéphanie de Montjoye¹, Stéphanie Dierckx², Adrien Nzeusseu Toukap³, Aleksandra Avramovska¹ and Patrick Durez⁴, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ³1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁴Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: The EULAR recommendations, updated in 20161 and 20192, propose the initiation of glucocorticoid (GC) therapy in combination with cDMARDs background therapy for every patient…
Abstract Number: 0151 • ACR Convergence 2020
More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)
Viviane Ta¹, Orit Schieir², Marie-France Valois³, Diane Tin⁴, Carol Hitchon⁵, Louis Bessette⁶, Carter Thorne⁴, Janet Pope⁷, Gilles Boire⁸, Edward Keystone⁹, Vivian Bykerk¹⁰, Susan Bartlett³ and Canadian Early Arthritis Cohort (CATCH) Investigators¹¹, ¹McGill University, Montreal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Laval University, Quebec, Canada, ⁷Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁸Universite de Sherbrooke, Sherbrooke, Canada, ⁹The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Although DMARDs are essential for early aggressive control of RA to reduce symptoms and disability, medication adherence is variable. Beliefs about the necessity of…
Abstract Number: 0804 • ACR Convergence 2020
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
Elise van Mulligen¹, Saad Ahmed¹, Angelique Weel², Mieke Hazes³, Annette van der Helm - van Mil⁴ and Pascal de Jong¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…
Abstract Number: 2017 • ACR Convergence 2020
Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis
Philip Mease¹, Désirée van der Heijde², Bruce Kirkham³, Georg Schett⁴, Ana-Maria Orbai⁵, Christopher Ritchlin⁶, Joseph Merola⁷, Luminita Pricop⁸, Xuan Zhu⁹, DavidA James⁹ and Gregory Ligozio⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸Novartis Pharmaceuticals Corporation, East Hanover, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Assessment of radiographic joint damage extent and progression is important in clinical trials evaluating treatments for psoriatic arthritis (PsA). Joint damage in patients with…
Abstract Number: 0219 • ACR Convergence 2020
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies
Raquel Dos-Santos¹, Sytske Anne Bergstra², J. M. Maassen², Thomas Huizinga² and CF Allaart², ¹Clinical University Hospital in Santiago de Compostela, Santiago de Compostela, Galicia, Spain, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Glucocorticoids are widely used in the treatment of rheumatoid arthritis (RA) patients. It is internationally recommended to taper and stop glucocorticoids as rapidly as…
Abstract Number: 1076 • ACR Convergence 2020
Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom
Lois Bolko¹, Kevin Didier², Jean-Hugues Salmon¹, Makoto Miyara³, Segolene Toquet², Amelie Servettaz², Yves Allenbach³, Olivier Benveniste⁴ and Baptiste Hervier⁵, ¹Maison Blanche Hospital, Reims, Champagne-Ardenne, France, ²Robert Debre Hospital, Reims, Champagne-Ardenne, France, ³Sorbonne Université, Paris, Ile-de-France, France, ⁴Sorbonne Université, paris, France, ⁵Saint-Louis Hospital, Paris, Ile-de-France, France
Background/Purpose: Anti-Synthetase Syndrome (ASyS) is a rare systemic autoimmune disease defined by a combination of pulmonary, muscle, joint, and skin manifestations and the presence of…
Abstract Number: 2036 • ACR Convergence 2020
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
Ariane Barbacki¹, Murray Baron², Mianbo Wang³, Yuqing Zhang⁴, Mandana Nikpour⁵ and Ada Man⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²Jewish General Hospital, Montreal, QC, Canada, ³Lady Davis institute for Medical Research, Montreal, QC, Canada, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, ⁵The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, ⁶University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality and characterized by the accrual of organ damage over time.…
Abstract Number: 0267 • ACR Convergence 2020
Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
Beatriz Tejera Segura¹, Irene Altabás González², Iñigo Rúa-Figueroa³, Natalia Pérez Veiga⁴, Victor del Campo Pérez⁵, Alejandro Olivé-Marqués⁶, Maria Galindo-Izquierdo⁷, Jaime Calvo-Alén⁸, Juan Ovalles-Bonilla⁹, Antonio Fernandez-Nebro¹⁰, Raul Menor Almagro¹¹, Eva Tomero Muriel¹², N. Del-val-del-amo¹³, Maria Esther Uriarte¹⁴, VM Martínez Taboada¹⁵, Jose Luis Andreu Sanchez¹⁶, Alina Lucica Boteanu¹⁷, Francisco Javier Narváez¹⁸, A Morasat¹⁹, Carlos Montilla Morales²⁰, JM Senabre Gallego²¹, Blanca Hernández Cruz²², Mariano Andrés²³, Eva Salgado Pérez²⁴, Mercedes Freire-González²⁵, Sergio Ramon Machin Garcia¹, Clara Moriano²⁶, Lorena Expósito²⁷, Clara E. Perez-Velasquez²⁸, ML Velloso-Feijoo²⁹, Ana Paula Cacheda³⁰, Nuria Lozano Rivas³¹, Gema Bonilla³², Marta Arévalo³³, Inmaculada Jimenez³⁴, VE Quevedo-Vila³⁵, Francisco Manero-Ruiz³⁶, Paloma García de la Peña³⁷, TR Vázquez-Rodríguez³⁸, J Ibáñez-Ruan³⁹, Tatiana Cobo-Ibañez⁴⁰ and Jose Maria Pego-Reigosa⁴¹, ¹Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁴Grupo IRIDIS, Universidad de Vigo, Vigo, Pontevedra, ⁵Hospital Universitario Meixoeiro, Vigo, Vigo, Pontevedra, Spain, ⁶Hospital Germans Trias i Pujol, Barcelona, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁰University of Malaga, Malaga, Spain, ¹¹Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ¹³Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁴Hospital Universitario Donostia, San Sebastian, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁶Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy, ¹⁸Hospital Bellvitge, BARCELONA, Spain, ¹⁹Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ²⁰Hospital Universitario de Salamanca, Salamanca, Spain, ²¹Hospital Marina Baixa, Alicante, Spain, ²²Universidad de Sevilla, Sevilla, Spain, ²³Hospital General Universitario de Alicante, Alicante, Spain, ²⁴Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ²⁵CHU Coruña, Coruña, Spain, ²⁶Complejo Asistencial Universitario de León, León, Spain, ²⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²⁸Basurto University Hospital, Bilbao, Spain, ²⁹Hospital Universitario de Valme, Sevilla, Spain, ³⁰Hospital son LLátzer, Palma de Mallorca, Spain, ³¹Hospital Clínico Universitario Virgen de Arrixaca, Murcia, Spain, ³²Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ³³Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, ³⁴Hospital Clínico San Ceciio Granada, Granada, Spain, ³⁵Hospital Comarcal de Monforte, Lugo, Spain, ³⁶Hospital Universitario Miguel Servet, Zaragoza, Spain, ³⁷Hospital HM, Madrid, Spain, ³⁸Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Hospital Povisa, Vigo, Pontevedra, Spain, ⁴⁰Hospital Infanta Sofia, Madrid, Spain, ⁴¹University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: To describe the GI manifestations of SLE in the RELESSER (Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology) cohort and…
Abstract Number: 1335 • ACR Convergence 2020
Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Dominic Seet¹, Li Wearn Koh², Preeti Dhanasekaran³, Man Hua Aw⁴, Rosa Lim Mui San², Siaw Ing Yeo⁴ and Manjari Lahiri¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, Singapore, ⁴Singapore General Hospital, Singapore, Singapore
Background/Purpose: To describe the demographic and clinical characteristics of patients with inflammatory arthritis (IA) initiating biologic disease modifying anti-rheumatic drugs (bDMARD) who use complementary and…
Abstract Number: 0271 • ACR Convergence 2020
External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus
Alicia Malone¹, Alexandra Legge¹ and John Hanly¹, ¹Dalhousie University, Halifax, NS, Canada
Background/Purpose: Using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, a frailty index (FI) was recently developed as a measure of susceptibility…
Abstract Number: 1436 • ACR Convergence 2020
Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study
Dennis Tabakovic¹, Rona Smith², David Jayne³ and Aladdin Mohammad⁴, ¹Lund University, Lund, Skane Lan, Sweden, ²University of Cambridge, Cambridge, United Kingdom, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: To study the incidence rate, predictors and outcome of stroke in patients with ANCA-associated vasculitis (AAV) within a defined population in southern Sweden.Methods: The…
Abstract Number: 0372 • ACR Convergence 2020
Tumor Necrosis Factor-α Receptor 2 Polymorphisms and Response to TNF Inhibitor Therapy in Patients with Psoriatic Arthritis
Sarah Rasheed¹, MacKenzie Dunlap¹, Jennifer Harvey¹, Connery Brennan¹, Yuxuan Jin², Unnikrishnan Chandrasekharan³ and M. Elaine Husni², ¹Cleveland Clinic Foundation, Cleveland, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have significantly improved the prognosis of patients with psoriatic arthritis (PsA); however, approximately 40% of patients do not achieve…
Abstract Number: 1487 • ACR Convergence 2020
Biclustering Reveals Potential Knee Osteoarthritis Phenotypes in Exploratory Analyses: Data from the Osteoarthritis Initiative
Amanda Nelson¹, Thomas Keefe², Todd Schwartz³, Richard Loeser¹, Yvonne Golightly⁴, Liubov Arbeeva¹ and J Marron², ¹University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina at Chapel Hill Dept of Biostatistics, Chapel Hill, NC, ⁴University of North Carolina at Chapel Hill Dept of Epidemiology, Chapel Hill, NC
Background/Purpose: To utilize novel methodologies to explore subgroups within the OAI clinical data.Methods: From the OAI baseline dataset (n=4796 individuals with or at risk of…
Abstract Number: 0384 • ACR Convergence 2020
Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease
Nancy Wareing¹, Ning Li², Elizabeth Volkmann³, Marka Lyons⁴, Michael Roth², Donald Tashkin² and Shervin Assassi¹, ¹University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²University of California, Los Angeles, Los Angeles, ³University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) patients have a prominent neutrophil gene expression signature. However, investigations into the pathophysiologic role of neutrophils in SSc are lacking. This…
Abstract Number: 1581 • ACR Convergence 2020
Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review
Michael Cunningham¹, Carolina Alvarez², Shruti Saxena Beem³, Todd Schwartz⁴ and Rumey Ishizawar⁵, ¹UNC Hospitals, Durham, NC, ²University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, ⁴University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Immune checkpoint inhibitors (ICIs) target checkpoint proteins PD-1/PD-L1 and CTLA-4 to activate and enhance the cytotoxic effects of T lymphocytes against tumor cells [1-2].…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.